CDC42BPA and cancer: In a screen of 757 human cancer cell lines from 40 different cancer types, BDP8900 and BDP9066 treatment produced consistent anti-proliferative effects, suggesting MRCK may be a valid therapeutic target in a number of cancers other than SCC (Unbekandt et al., 2018).